skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Efficacy of Salvage Radiotherapy Plus 2-Year Androgen Suppression for Postradical Prostatectomy Patients With PSA Relapse

Abstract

Purpose: To determine the efficacy of a combined approach of radiotherapy (RT) plus 2-year androgen suppression (AS) as salvage treatment for prostate-specific antigen (PSA) relapse after radical prostatectomy (RP). Methods and Materials: Seventy-five patients with PSA relapse after RP were treated with salvage RT plus 2-year AS, as per a pilot, prospective study. AS started within 1 month after completion of salvage RT and consisted of nilutamide for 4 weeks and buserelin acetate depot subcutaneously every 2 months for 2 years. Relapse-free rate including freedom from PSA relapse was estimated using the Kaplan-Meier method. PSA relapse was defined as a PSA rise above 0.2 ng/mL with two consecutive increases over a minimum of 3 months. A Cox regression analysis was performed to evaluate prognostic factors for relapse. Results: Median age of the cohort was 63 years at the time of salvage RT. Median follow-up from salvage RT was 6.4 years. All achieved initially complete PSA response (< 0.2) with the protocol treatment. Relapse-free rate including the freedom from PSA relapse was 91.5% at 5 years and 78.6% at 7 years. Overall survival rate was 93.2% at both 5 and 7 years. On Cox regression analysis, pT3 stage and PSA relapsemore » less than 2 years after RP were significant prognostic factors for relapse. Conclusion: The combined treatment of salvage RT plus 2-year AS yielded an encouraging result for patients with PSA relapse after RP and needs a confirmatory study.« less

Authors:
 [1]; ; ; ; ; ;  [2];  [3]
  1. Mayo Clinic, Department of Radiation Oncology, Rochester, MN (United States)
  2. Odette Cancer Centre, Department of Radiation Oncology, University of Toronto, Toronto, ON (Canada)
  3. Auckland Hospital, Department of Radiation Oncology (New Zealand)
Publication Date:
OSTI Identifier:
21367489
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 75; Journal Issue: 4; Other Information: DOI: 10.1016/j.ijrobp.2008.12.049; PII: S0360-3016(09)00013-3; Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ANDROGENS; ANTIGENS; INHIBITION; NEOPLASMS; PROSTATE; RADIOTHERAPY; REGRESSION ANALYSIS; ANDROSTANES; BODY; DISEASES; GLANDS; HORMONES; MALE GENITALS; MATHEMATICS; MEDICINE; NUCLEAR MEDICINE; ORGANIC COMPOUNDS; ORGANS; RADIOLOGY; STATISTICS; STEROID HORMONES; STEROIDS; THERAPY

Citation Formats

Choo, Richard, Danjoux, Cyril, Gardner, Sandra, Morton, Gerard, Szumacher, Ewa, Loblaw, D Andrew, Cheung, Patrick, and Pearse, Maria. Efficacy of Salvage Radiotherapy Plus 2-Year Androgen Suppression for Postradical Prostatectomy Patients With PSA Relapse. United States: N. p., 2009. Web. doi:10.1016/j.ijrobp.2008.12.049.
Choo, Richard, Danjoux, Cyril, Gardner, Sandra, Morton, Gerard, Szumacher, Ewa, Loblaw, D Andrew, Cheung, Patrick, & Pearse, Maria. Efficacy of Salvage Radiotherapy Plus 2-Year Androgen Suppression for Postradical Prostatectomy Patients With PSA Relapse. United States. https://doi.org/10.1016/j.ijrobp.2008.12.049
Choo, Richard, Danjoux, Cyril, Gardner, Sandra, Morton, Gerard, Szumacher, Ewa, Loblaw, D Andrew, Cheung, Patrick, and Pearse, Maria. 2009. "Efficacy of Salvage Radiotherapy Plus 2-Year Androgen Suppression for Postradical Prostatectomy Patients With PSA Relapse". United States. https://doi.org/10.1016/j.ijrobp.2008.12.049.
@article{osti_21367489,
title = {Efficacy of Salvage Radiotherapy Plus 2-Year Androgen Suppression for Postradical Prostatectomy Patients With PSA Relapse},
author = {Choo, Richard and Danjoux, Cyril and Gardner, Sandra and Morton, Gerard and Szumacher, Ewa and Loblaw, D Andrew and Cheung, Patrick and Pearse, Maria},
abstractNote = {Purpose: To determine the efficacy of a combined approach of radiotherapy (RT) plus 2-year androgen suppression (AS) as salvage treatment for prostate-specific antigen (PSA) relapse after radical prostatectomy (RP). Methods and Materials: Seventy-five patients with PSA relapse after RP were treated with salvage RT plus 2-year AS, as per a pilot, prospective study. AS started within 1 month after completion of salvage RT and consisted of nilutamide for 4 weeks and buserelin acetate depot subcutaneously every 2 months for 2 years. Relapse-free rate including freedom from PSA relapse was estimated using the Kaplan-Meier method. PSA relapse was defined as a PSA rise above 0.2 ng/mL with two consecutive increases over a minimum of 3 months. A Cox regression analysis was performed to evaluate prognostic factors for relapse. Results: Median age of the cohort was 63 years at the time of salvage RT. Median follow-up from salvage RT was 6.4 years. All achieved initially complete PSA response (< 0.2) with the protocol treatment. Relapse-free rate including the freedom from PSA relapse was 91.5% at 5 years and 78.6% at 7 years. Overall survival rate was 93.2% at both 5 and 7 years. On Cox regression analysis, pT3 stage and PSA relapse less than 2 years after RP were significant prognostic factors for relapse. Conclusion: The combined treatment of salvage RT plus 2-year AS yielded an encouraging result for patients with PSA relapse after RP and needs a confirmatory study.},
doi = {10.1016/j.ijrobp.2008.12.049},
url = {https://www.osti.gov/biblio/21367489}, journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 4,
volume = 75,
place = {United States},
year = {Sun Nov 15 00:00:00 EST 2009},
month = {Sun Nov 15 00:00:00 EST 2009}
}